382 results on '"Shimabukuro, Tom"'
Search Results
2. Overview of U.S. COVID-19 vaccine safety surveillance systems
3. Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic
4. COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic
5. A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States
6. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
7. Contributors
8. Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
9. Outbreak of Highly Pathogenic Avian Influenza A(H5N1) Viruses in U.S. Dairy Cattle and Detection of Two Human Cases--United States, 2024
10. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna) : Update from the Advisory Committee on Immunization Practices — United States, July 2021
11. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
12. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients : Update from the Advisory Committee on Immunization Practices — United States, June 2021
13. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
14. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
15. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
16. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021
17. SARS-CoV-2 Infection Among Hospitalized Pregnant Women : Reasons for Admission and Pregnancy Characteristics — Eight U.S. Health Care Centers, March 1–May 30, 2020
18. Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020
19. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021
20. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020
21. Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose
22. Characteristics and Risk Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March-April 2020
23. Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months-5 Years--United States, June 17, 2022-May 7, 2023
24. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
25. Vaccine Administration Errors Involving Recombinant Zoster Vaccine — United States, 2017–2018
26. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years--United States, October 12-January 1, 2023
27. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System
28. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons--43 U.S. Jurisdictions, July 31-October 1, 2022
29. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak--United States, May 22-October 21, 2022
30. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged [greater than or equal to]12 Years--United States, August 31-October 23, 2022
31. COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years--United States, June 18, 2022-August 21,2022
32. Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years — United States, July 13, 2022–March 13, 2023
33. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990–2013
34. White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink
35. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years--United States, May 17-July 31, 2022
36. Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged [greater than or equal to]50 Years--United States, March 29, 2022-July 10, 2022
37. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged >12 Years with Presumed Immunocompromise Status--United States, January 12, 2022-March 28, 2022
38. Vaccine Safety
39. List of Contributors
40. COVID-19 Vaccine Safety Inquiries to the Centers for Disease Control and Prevention Immunization Safety Office
41. Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective
42. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013–2015
43. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12
44. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
45. Deaths following vaccination: What does the evidence show?
46. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000–2013
47. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013–June 2014
48. Adverse Events following Haemophilus influenzae Type b Vaccines in the Vaccine Adverse Event Reporting System, 1990-2013
49. COVID-19 Vaccine Safety First Year Findings in Adolescents
50. Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997–2013
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.